Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea

Trial Profile

Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2018

At a glance

  • Drugs Oxymetazoline (Primary)
  • Indications Rosacea
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 27 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 04 May 2018 Planned End Date changed from 6 May 2018 to 29 May 2018.
    • 04 May 2018 Planned primary completion date changed from 6 May 2018 to 29 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top